Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

V
V. Volpi, Emanuela

University of Westminster
1021 - Transcriptional correlation analysis of the CD180/MD-1 complex and toll-like receptors and signaling lymphocyte activation family receptors in chronic lymphocytic leukemia.
Emanuela V. Volpi
Favorite
Vainer, Noomi

Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center
1101 - Association between hypertension and overall survival in chronic lymphocytic leukemia
Noomi Vainer
Favorite
Valkovic, Toni

UHC Rijeka, Rijeka School of Medicine
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Toni Valkovic
Favorite
Van Bruggen, Jaco A.C.

Amsterdam University Medical Centers
1024 - Impaired mitochondrial metabolism drives T-cell dysfunction in chronic lymphocytic leukemia
Jaco A.C. Van Bruggen
Favorite
Van Dyke, Daniel

Mayo Clinic
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Daniel Van Dyke
Favorite
1134 - High deletion burden identified by whole genome sequencing is associated with enhanced risk in del17p CLL patients
Daniel Van Dyke
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Daniel Van Dyke
Favorite
Van Nieuwerburgh, Filip

Laboratory of Pharmaceutical Biotechnology, Ghent University
1036 - Chronic lymphocytic leukemia extracellular vesicles induce the differentiation of monocytes into nurse-like cells
Filip Van Nieuwerburgh
Favorite
VanDerMeid, Karl

Wilmot Cancer Institute / University of Rochester Medical Center
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Karl VanDerMeid
Favorite
Vanguru, Vinay

NSW Health
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Vinay Vanguru
Favorite
VanMorckhoven, David

Jules Bordet Institute - Laboratory of Clinical Cell Therapy
1036 - Chronic lymphocytic leukemia extracellular vesicles induce the differentiation of monocytes into nurse-like cells
David VanMorckhoven
Favorite
Varettoni, Marzia

Divisione di Ematologia, Fondazione IRCCS Policlinico San Matteo
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Marzia Varettoni
Favorite
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Marzia Varettoni
Favorite
Vasyutina, Elena

University Hospital of Cologne
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Elena Vasyutina
Favorite
Vavoulis, Dimitris

Oxford Molecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
1202 - T cell type abundance and gene expression patterns in the context of clinical progression of treatment-naïve CLL/MBL patients from the OxPLoreD study
Dimitris Vavoulis
Favorite
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Dimitris Vavoulis
Favorite
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Dimitris Vavoulis
Favorite
Veldhuis, Gerrit-Jan

Department of Hematology, Antonius Ziekenhuis
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Gerrit-Jan Veldhuis
Favorite
Vermeulen, Mónica

IMEX-CONCIET-ANM
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Mónica Vermeulen
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Mónica Vermeulen
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Mónica Vermeulen
Favorite
Verner, Emma

Concord Repatriation General Hospital, Concord, NSW, Australia; University of Sydney
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Emma Verner
Favorite
Vidal Manceñido, María Jesús

Hospital de León
1161 - ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
María Jesús Vidal Manceñido
Favorite
Vidler, Jennifer

Haematology. King’s College Hospital NHS Foundation Trust
1028 - Peripheral Blood CXCR4hiCD5hi Chronic Lymphocytic Leukaemia Cells are Primed for Returning to the Lymph Nodes for further Activation and Proliferation
Jennifer Vidler
Favorite
villarubia, Jesus
1030 - Immunophenotypic Characterization of Richter Syndrome Diffuse Large B-Cell Lymphoma Type and Comparison with the Original Chronic Lymphocytic Leukemia
Jesus villarubia
Favorite
Villemagne, Bruno

Hematology Department, Centre Hospitalier Départemental
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Bruno Villemagne
Favorite
Vilque, Jean-Pierre

CHU Caen
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Jean-Pierre Vilque
Favorite
Vimal, Mona

Biomea Fusion
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Mona Vimal
Favorite
Vincelli, Iolanda Donatella

A.O. "Bianchi-Melacrino-Morelli", Via Giuseppe Melacrino 21, 89124
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Iolanda Donatella Vincelli
Favorite
Virta, Camilla

Department of Health Security, Finnish Institute for Health and Welfare
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Camilla Virta
Favorite
Visentin, Andrea

Università degli Studi di Padova
1016 - DEFACTINIB AFFECTS CHRONIC LYMPHOCYTIC LEUKEMIA CELL SURVIVAL WITH ADDITIVE EFFECT IN COMBINATION WITH BTK INHIBITORS
Andrea Visentin
Favorite
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Andrea Visentin
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Andrea Visentin
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Andrea Visentin
Favorite
Viswanatha, David

Mayo Clinic
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
David Viswanatha
Favorite
Vitale, Candida

1 Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3,10126, Torino, Italy
2 Department of Molecular Biotechnology and Health Sciences, University of Torino
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Candida Vitale
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Candida Vitale
Favorite
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Candida Vitale
Favorite
Vit, Filippo
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Filippo Vit
Favorite
Vles, Raymond

CLL Canada
1108 - Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia
Raymond Vles
Favorite
Vodárek, Pavel

4th Department of Internal Medicine – Hematology, University Hospital and Charles University Faculty of Medicine in Hradec Králové
1136 - Serum Monoclonal Immunoglobulin Predicts Inferior Prognosis in Patients Treated for Chronic Lymphocytic Leukemia
Pavel Vodárek
Favorite
1156 - Real-world Effectiveness and Safety of Tixagevimab/Cilgavimab Lower Dosage Regimen in Pre-Exposure Prophylaxis in Patients Undergoing Treatment for Chronic Lymphocytic Leukemia
Pavel Vodárek
Favorite
1215 - Unveiling the Spectrum of Genetic Alterations in Relapsed/Refractory CLL Patients on Targeted Inhibitors: A Prospective Unicentric Study
Pavel Vodárek
Favorite
1217 - Evolution of natural history and prolongation of overall survival in patients with chronic lymphocytic leukemia: analysis of a long-term follow-up of an unselected cohort in the Hradec Králové district, Czech Republic.
Pavel Vodárek
Favorite
Voillat, Laurent
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Laurent Voillat
Favorite
vom Stein, Alexander

Department I for Internal Medicine, University Hospital Cologne
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Alexander vom Stein
Favorite
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Alexander vom Stein
Favorite
von Lom, Anton
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Anton von Lom
Favorite
Vrbacký, Filip

4th Department of Internal Medicine – Hematology, University Hospital and Charles University Faculty of Medicine in Hradec Králové
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Filip Vrbacký
Favorite
1215 - Unveiling the Spectrum of Genetic Alterations in Relapsed/Refractory CLL Patients on Targeted Inhibitors: A Prospective Unicentric Study
Filip Vrbacký
Favorite
Vrkljan, Anamarija

University Hospital Dubrava
1019 - Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy
Anamarija Vrkljan
Favorite
Vydzhak, Olga
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Olga Vydzhak
Favorite
Vyskočil, Filip

Charles University Faculty of Medicine in Hradec Králové
1136 - Serum Monoclonal Immunoglobulin Predicts Inferior Prognosis in Patients Treated for Chronic Lymphocytic Leukemia
Filip Vyskočil
Favorite